Business Wire

SESIP Paves the Way for IoT Manufacturers to Meet New European Cybersecurity Rules

12.12.2024 09:00:00 CET | Business Wire | Press release

Share

GlobalPlatform’s SESIP methodology (EN 17927) offers a streamlined, cost-effective security framework for connected devices and components to conform to the EU’s new Cyber Resilience Act

GlobalPlatform is calling for manufacturers of connected devices and components to adopt its “Security Evaluation Standard for IoT Platforms” (SESIP) methodology to demonstrate conformance with the European Union’s new Cyber Resilience Act (CRA), which comes into force this month. The CRA aims to strengthen and harmonize cybersecurity across the EU by creating a new legal framework for all products that connect to the internet.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241211681976/en/

null

(Graphic: Business Wire)

The enactment of the CRA puts into place mandatory cybersecurity rules that span the entire lifecycle of a digital product sold in the EU. The CRA was published in the Official Journal of the European Union last month and becomes law on December 11, 2024. Product manufacturers will have 36 months to fully comply with the legislation. The Act will eventually require all relevant products to comply with the rules in order to obtain the CE marking, a mandatory market requirement for issuing products in Europe.

As an internationally recognized standard for IoT security evaluation, SESIP is key to meeting the requirements mandated by the CRA. It provides manufacturers with a proven methodology for conducting security evaluations of software and hardware components across their products and supply chains. SESIP is recognized as a standard by CENELEC, the European Standardization Organization, as EN 17927. It also aligns with many other legislation and vertical certification schemes around the world, including the Cyber Trust Mark in the US.

The methodology is being used to certify components, platforms, and modules from a range of companies and is supported by a growing ecosystem of security providers, certification bodies (CBs), security laboratories, and other stakeholders. GlobalPlatform continues to support the growth and governance of the SESIP ecosystem. SGS Brightsight has recently been accredited as a SESIP CB following approval from the Spanish national accreditation body (ENAC), becoming the second SESIP CB after TrustCB.

“Industry support for SESIP is building at this critical juncture for IoT manufacturers operating in Europe,” said Gil Bernabeu, CTO of GlobalPlatform. “The Cyber Resilience Act is vital to protecting consumers and businesses by embedding security features into the heart of the connected devices we use every day, providing a cybersecurity framework that spans the design, development, and maintenance of digital products.

“However, this landmark legislation presents a range of compliance challenges for manufacturers of connected devices and the components used in these products,” continued Bernabeu. “SESIP simplifies conformity with the new regulations by providing a unified framework for comprehensive security evaluation, reducing cost, risk, and time to market. We look forward to expanding the SESIP ecosystem to help multiple industry sectors meet the requirements of the new European regulations. It will also enable international manufacturers to reuse their security evaluation investments to demonstrate conformance to non-European regulations.”

The SESIP methodology is already mapped to other standards and regulations such as ETSI, (EN 303645 / TS 103732), ISO/IEC (62443-4-2), RED (EN 18031), UNECE WP.29 (ISO/SAE 21434) and NIST (NIST 8259 / NIST 8425). It is also being used by schemes such as PSA Certified, and standardization bodies including the Car Connectivity Consortium and the Wireless Power Consortium. In addition to Europe, SESIP is being adopted around the world in key markets such as China, where an agreement was recently reached between GlobalPlatform and China’s National Financial Technology Certification Center (NFTC).

GlobalPlatform has a number of initiatives in place to help accelerate SESIP adoption. A training program has been launched and available for any interested party. It has also launched the SESIP Adopters community to give non-members the ability to keep up to date with relevant technical documents and showcase certified SESIP products.

For more information on SESIP please visit: https://globalplatform.org/sesip/

About GlobalPlatform

GlobalPlatform is a technical standards organization that enables the efficient launch and management of innovative, secure-by-design digital services and devices, which deliver end-to-end security, privacy, simplicity, and convenience to users. It achieves this by providing standardized technologies and certifications that empower technology and service providers to develop, certify, deploy, and manage digital services and devices in line with their business, security, regulatory and data protection needs. GlobalPlatform technologies are used in billions of smart cards, smartphones, wearables and other connected and IoT devices.

GlobalPlatform standardized technologies and certifications are developed through effective industry-driven collaboration, led by multiple diverse member companies working in partnership with industry and regulatory bodies and other interested parties from around the world.

globalplatform.org | Twitter / X | LinkedIn | YouTube | GitHub | WeChat

View source version on businesswire.com: https://www.businesswire.com/news/home/20241211681976/en/

null

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release

- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C

Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release

The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag

Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda

Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release

Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm

No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 14:48:00 CEST | Press release

Rapid growth shows strong demand for a new trading model where users can make market predictions without risking their own capital Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye